Tobira brings in $31 million to fund CCR5 antagonist for HIV
This article was originally published in Scrip
Executive Summary
Tobira Therapeutics, a US firm focused on developing new antivirals for HIV, has closed a $31 million series B financing led by new investor Novo A/S.